When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

EverQuote Inc. (NASDAQ:EVER) is one of the best fintech stocks to invest in. On February 23, EverQuote announced earnings for the full year 2025, with total revenue surging 38% to $692.5 million. This was fueled by the automotive insurance vertical, which grew 41% to $629.8 million, alongside a 20% increase in home and renters insurance revenue. The company’s focus on operational efficiency through AI integration boosted its bottom line, as adjusted EBITDA jumped 62% year-over-year to $94.6 million. Q4 m ...

CME Group Inc. (NASDAQ:CME) is one of the best fintech stocks to invest in. On February 4, CME Group announced financial results for 2025, underscored by annual revenues of $6.5 billion. Average daily volume/AD grew 6% to 28.1 million contracts, driven by a 12% increase in commodities trading and a 5% rise in financials. The company reported record annual adjusted operating income, net income, and adjusted EPS of $11.20. Q4 for CME Group Inc. (NASDAQ:CME) was particularly strong, marking the highest four ...

Group 1 - The focus is on maintaining a delta neutral portfolio, aiming to be long/short simultaneously to benefit from market volatility [1] - The strategy involves using options for entering and exiting trades, primarily targeting small and mid-sized companies for market opportunities [1]

Intercontinental Exchange Inc. (NYSE:ICE) is one of the best fintech stocks to invest in. On February 5, Intercontinental Exchange announced its earnings for the full year 2025, reporting a 7% year-over-year increase to $9.9 billion. This growth translated into a rise in profitability, with GAAP diluted earnings per share jumping 21% to $5.77 and adjusted diluted EPS rising 14% to $6.95. Q4 revenue totaled $2.50 billion, which was a 7.79% improvement. Performance was strong across all primary business se ...

Coupang (NYSE:CPNG), South Korean e-commerce and technology company, closed Friday at $19.08, up 1.98%. The stock inched higher as investors reacted to stabilization signs following the late‑2025 data incident and are watching how management’s recovery plan and buybacks support earnings quality. Trading volume reached 51.2 million shares, about 125% above its three-month average of 22.7 million shares. Coupang IPO'd in 2021 and has fallen 61% since going public. How the markets moved today S&P 500 slipped ...

With the threat of a ballot initiative looming, a slate of auto dealers in Washington have come out in support of EV makers Rivian and Lucid Motors in their pursuit of direct sales to consumers. Electric automakers have fought for years to change the state law that only allows Tesla to directly sell cars, operate showrooms and offer test drives to potential customers in Washington. The rule exists to prevent manufacturers from competing against franchised dealerships. In December, Rivian began taking steps ...

Anywhere from $40 billion to $150 billion of leveraged loans packaged into US collateralized loan obligations could be disrupted by the artificial intelligence boom, according to JPMorgan Chase & Co. That’s because those loans fall within sectors most associated with AI risk, according to the Wall Street lender, which released its estimate as a recap of the SFVegas 2026 conference where software’s impact on corporate CLOs was “the topic du jour.” Most Read from Bloomberg CLOs offer investors exposure t ...

Core Viewpoint - The article emphasizes the importance of conducting thorough due diligence and research before making any investment decisions, highlighting that past performance does not guarantee future results [2][3]. Group 1 - The author does not hold any stock, options, or similar derivative positions in the companies mentioned and has no plans to initiate such positions in the near future [1]. - The article clarifies that it is not financial advice and that the author is not a licensed financial advisor, urging investors to understand the risks involved in various trading styles [2]. - It is noted that investing in European and non-US stocks may involve specific withholding tax risks, and investors are encouraged to consult tax professionals regarding these matters [2]. Group 2 - The article states that Seeking Alpha does not provide recommendations or advice on the suitability of investments for particular investors, and opinions expressed may not reflect the views of Seeking Alpha as a whole [3]. - The authors of the articles include both professional and individual investors, some of whom may not be licensed or certified by any regulatory body [3].

Core Viewpoint - Sharp Therapeutics Corp. has successfully closed the first tranche of its non-brokered private placement for unsecured convertible notes, raising a total of US$500,000 through the issuance of 500 notes, with proceeds allocated for general working capital purposes [1]. Group 1: Note Offering Details - Each note has a principal amount of US$1,000 and is convertible into common shares at a price of US$2.00 per share, with a conversion option available until 12 months post-closing [2]. - The notes carry an interest rate of 6.0% per annum, calculated as simple interest and payable in cash on the maturity date [3]. - The first tranche included participation from insiders, with STX Partners, LLC acquiring 200 notes for US$200,000, Newlin Investment Company 1, LLC acquiring 100 notes for US$100,000, and others, totaling 350 notes for US$350,000 [4]. Group 2: Regulatory and Compliance Information - The insider participation in the first tranche is classified as a related-party transaction, exempt from formal valuation or minority shareholder approval under Multilateral Instrument 61-101, as the transaction does not exceed 25% of the company's market capitalization [5]. - The company did not file a material change report prior to the closing due to the timing of insider participation details, and no new Control Person will be created as a result of this tranche [6]. Group 3: Future Commitments and Offerings - STX has committed an additional US$800,000 for future contributions in four tranches of US$200,000 each, scheduled for March and April 2026 [7]. - The notes were offered through private placement in Canada and the United States, adhering to applicable exemptions from prospectus requirements [8]. Group 4: Company Overview - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies and computationally optimized compound libraries [10].